RECRUITING

FMT in Gut aGVHD Treated

Department of Hematology of First Affiliated Hospital of Soochow University

NCT03148743•The First Affiliated Hospital of Soochow University

Summary

With the stem cell transplanting increasing, patients which effected with gut GVHD were also increased. To evaluation the safety and efficacy of FMT for gut GVHD,patients with gut GVHD were recruited.

Eligibility

Age

10 - 60 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•gut GVHD

Exclusion Criteria

•Age\>60; or Age\<10

Locations (1)

中国

Suzhou, Jiangsu, China

Key Dates

Start Date

May 16, 2017

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

March 19, 2025

Enrollment

50

ESTIMATED participants

Conditions

Acute-graft-versus-host Disease

Interventions

Fecal microbiota

BIOLOGICAL

Contacts

xiaofei qi

CONTACT

1-86-512-67780410 qixiaofei@suda.edu.cn

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

NCT04291261

Acute-graft-versus-host Disease

View study

COMPLETEDPHASE3

Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation

NCT05149365

Acute-graft-versus-host DiseaseAllogeneic Hematopoietic Stem Cell Transplantation

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

COMPLETED

PHASE1